TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04771221

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pH metry
Description: The collection of mucus from the laryngopharynx to determine the acid-base values through pH-metry.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pH metry
Description: The collection of mucus from the laryngopharynx to determine the acid-base values through pH-metry.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pH metry
Description: The collection of mucus from the laryngopharynx to determine the acid-base values through pH-metry.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Filling out the questionnaire
Description: Completion of the questionnaire index of reflux symptoms. An analysis of the results of the effectiveness of this method in patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching will be carried out. Evaluation results range from 0 to 5, where 0 is an indicator of no problem, and 5 is an indicator of a serious problem

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Filling out the questionnaire
Description: Completion of the questionnaire index of reflux symptoms. An analysis of the results of the effectiveness of this method in patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching will be carried out. Evaluation results range from 0 to 5, where 0 is an indicator of no problem, and 5 is an indicator of a serious problem

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Filling out the questionnaire
Description: Completion of the questionnaire index of reflux symptoms. An analysis of the results of the effectiveness of this method in patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching will be carried out. Evaluation results range from 0 to 5, where 0 is an indicator of no problem, and 5 is an indicator of a serious problem

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic laryngoscopy
Description: Video laryngoscopy and assessment of the presence / severity of the symptoms. Evaluation results range from 0 to 4, where 0 is an indicator of no problem, and 4 is an indicator of a serious problem

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic laryngoscopy
Description: Video laryngoscopy and assessment of the presence / severity of the symptoms. Evaluation results range from 0 to 4, where 0 is an indicator of no problem, and 4 is an indicator of a serious problem
Study: NCT06733090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine glucanate solution
Description: 0.2% chlorhexidine glucanate solution
Study: NCT06733051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golidocitinib
Description: 150 mg, administered once daily from Day 1 to Day 21 (D1-D21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benmelstobart
Description: 1200 mg, administered on Day 1 (D1) of every cycle
Study: NCT06733922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETNATM-ProgMS
Description: To that end, the study will use the patented investigational ETNATM-ProgMS SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision. Of note, investigational versions of this SaMD are used for the purpose of clinical research only and will not be commercialized.
Study: NCT06732323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG401
Description: IV infusion on day 1,8, and 15 of each 28 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice Chemotherapy
Description: Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin
Study: NCT06732557

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Traditional treatments
Description: Isometric exercise for deep neck flexors and sub occipital release

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional treatments
Description: Isometric exercise for deep neck flexors and sub occipital release

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatments
Description: Isometric exercise for deep neck flexors and sub occipital release

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: Muscle energy technique for upper trapezius, elevator scapulae and sternocleidomastoid
Study: NCT04771221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic laryngoscopy
Description: Video laryngoscopy and assessment of the presence / severity of the symptoms. Evaluation results range from 0 to 4, where 0 is an indicator of no problem, and 4 is an indicator of a serious problem

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic voice analysis
Description: acoustic analysis of the voice was performed in singers with voice disorders before and after treatment using program of the Lingwaves
Study: NCT06732557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan Mobilization
Description: Mulligan mobilization in the form of SNAGS for rotation, lateral flexion, extension and flexion
Study: NCT06732401

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study: NCT06733909

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restoration of Pulpotomized Primary Molars using NuSmile Zirconia crowns
Description: Prefabricated pediatric Zirconia crowns offer an excellent alternative to full-coverage crowns when restoring deciduous teeth with a sizeable carious defect. These crowns have high flexural strength, allowing them to resist crack propagation. The additional benefits of these crowns are the ability to replace metals due to extremely high strength and toughness, higher resistance to chemicals, and superior erosion resistance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restoration of Pulpotomized Primary Molars using BioFlx crowns
Description: The Bioflex crown has been introduced in pediatric practice as a synthetic crown that will provide better adaptation, durability, and ease of handling with improved aesthetic properties compared to conventional crowns. The Bioflex crown may provide a promising result in terms of the clinician's and parental satisfaction as aesthetic is a prime concern for parents and children in this era. The limitations of the studies on this type of crowns will require more studies with more detailed clinical observation and larger sample size to provide more rigorous results.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restoration of Pulpotomized Primary Molars using Digital VITA ENAMIC crowns (CAD/CAM blanks)
Description: is a hybrid ceramic with a dual network structure that combines the best characteristics of ceramic and composite. Fast and efficient CAM fabrication; for minimally invasive reconstructions, tooth-like material properties.
Study: NCT06733220

Intervention type: PROCEDURE
Intervention: Surgery for strabismus
Description: Patients will undergo surgery to correct strabismus, congenital or acquired

Intervention type: PROCEDURE
Intervention: Surgery for strabismus
Description: Patients will undergo surgery to correct strabismus, congenital or acquired
Study: NCT06732336

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-trastuzumab
Description: Patients will receive an intravenous dose of 0.5 MBq/kg (max 60 MBq) of 89Zr-trastuzumab in order to perform a PET imaging session 3-6 days later.
Study: NCT06732232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19/CD20/BCMA CAR-T
Description: CD19/CD20/BCMA CAR T therapy
Study: NCT06121882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfragmented Adipose Tissue derived using the Lipogems® System
Description: Intra-articular knee injection of Microfragmented Adipose Tissue (MFat) derived using the Lipogems® System.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Injection
Description: Intra-articular knee injection of saline
Study: NCT06723275

Intervention type: OTHER
Intervention: Standardized assessments, guided tumor biopsy and biobanking
Description: Standardized assessment of Scores~* Guided tumor biopsy in patients listed for hepatocellular carcinoma with active tumor at listing in centers not perfoming tumor biopsy on a routine basis~* Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs~* Urine sampling for biobanking and subsequent analysis of innovative biomarkers~* Ascite sampling for biobanking and subsequent analysis~* Tumor sampling for biobanking and subsequent analysis~* Centralized assay for routine biomarkers

Intervention type: OTHER
Intervention: Standardized assessments and biobanking
Description: * Standardized assessment of Scores~* Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs~* Urine sampling for biobanking and subsequent analysis of innovative biomarkers~* Ascite sampling for biobanking and subsequent analysis~* Tumor sampling for biobanking and subsequent analysis~* Centralized assay for routine biomarkers

Intervention type: OTHER
Intervention: Standardized assessments and biobanking
Description: * Standardized assessment of Scores~* Additional blood sampling for biobanking and subsequent analysis of innovative biomarkers and OMICs~* Urine sampling for biobanking and subsequent analysis of innovative biomarkers~* Ascite sampling for biobanking and subsequent analysis~* Tumor sampling for biobanking and subsequent analysis~* Centralized assay for routine biomarkers
Study: NCT06748937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD
Description: Cohort 1 Arm 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpibectir 45 mg OD plus Ethionamide 250 mg OD
Description: Cohort 1 Arm 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
Description: Cohort 2 Arm 4
Study: NCT06211426

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT05768828

Intervention type: DIAGNOSTIC_TEST
Intervention: Nociceptive Blink Reflex
Description: Noxious trigeminal electrical stimulation at different interstimulus intervals using 1.5x the pain threshold in order to provoke a release of trigeminal CGRP

Intervention type: DIAGNOSTIC_TEST
Intervention: Nociceptive Blink Reflex
Description: Noxious trigeminal electrical stimulation at different interstimulus intervals using 1.5x the pain threshold in order to provoke a release of trigeminal CGRP
Study: NCT04576806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body temperature
Description: Warming of administered fluid bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluid bolus
Description: Administration of fluid bolus of crystalloid of 500ml over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid bolus
Description: Administration of fluid bolus of crystalloid of 500ml over 15 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room temperature
Description: Cooling of administered fluid bolus
Study: NCT04965610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoxygenation with High Flow Nasal Cannula
Description: Preoxygenation for 5 minutes via High Flow Nasal Cannula. After induction of anaesthesia apnoeic oxygenation with HFNC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation via face mask
Description: Preoxygenation for 5 minutes via face mask. After induction of anaesthesia apnoeic oxygenation with tight fitting face mask
Study: NCT04047212

Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy for oral cancer
Description: surgical biopsy is to be taken for diagnosis of oral cancer or premalignant lesions

Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy for oral cancer
Description: surgical biopsy is to be taken for diagnosis of oral cancer or premalignant lesions

Intervention type: DIAGNOSTIC_TEST
Intervention: periodontal examination
Description: Periodontal clinical examination to all by periodontal charting

Intervention type: DIAGNOSTIC_TEST
Intervention: periodontal examination
Description: Periodontal clinical examination to all by periodontal charting
Study: NCT04931628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvianolic Acid
Description: salvianolic acid, injection, 100mg+0.9%NaCl 250ml, qd, 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: 0.9% NaCl
Study: NCT06742749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal level
Description: For the proximal level of psoas tenotomy at the pelvic brim, the hip was slightly flexed to relax the iliopsoas muscle; the iliacus muscle fibers were retracted anteriorly until the deeply seated posteromedially psoas tendon was isolated and transected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal level
Description: For the distal level of iliopsoas tenotomy just above the lesser trochanter, the thigh was put in the position of FABER (flexion, abduction, and external rotation). A curved right-angle hemostatic clamp was used to retract and bring the iliopsoas tendon into the field. Then, the tendinous fibers were transected.
Study: NCT06752460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EF192B
Description: EF192B will be applied after the tape strriping procedure and will be reapplied after 12 hours.
Study: NCT06752044

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-based peptide vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-based peptide vaccine
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study: NCT06752408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib
Description: Aumolertinib will be administered orally at a dose of 110 mg per time, Q.D.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
Study: NCT06754865

Intervention type: DRUG
Intervention: Xiyanping injection+ antibiotic
Description: Xiyanping injection+ antibiotic

Intervention type: DRUG
Intervention: Antibiotic
Description: Antibiotic
Study: NCT06754748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Description: 11 g caffeinated coffee made with 200 ml water was given to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Description: 11 g decaffeinated coffee made with 200 ml water was given to participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 200 ml water was given to participants.
Study: NCT06752330

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Use of probiotics during oral hygiene at home
Description: The probiotic used in the study is Bifidobacterium Lactis HN019, distributed com-mercially in Italy by Curasept (Curasept Prevent®, Curasept S.p.A., Saronno, VA, Italy), with added Kluyveromyces Marxianus Fragilis B0399, colostrum and biotin. The probiotic was taken by patients following the manufacturer's directions via 2 chewable tablets daily, morning and evening, after normal daily oral hygiene, achieving daily average values of B. Lactis HN019 of 2\*107 CFU and Kluyveromyces marxianus fragilis B0399 of 2\*109 CFU.
Study: NCT06755879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital game-based learning activity
Description: learning interventions to prevent surgical site infections with a digital game-based learning activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional method
Description: Evaluation of the effectiveness of students' learning of interventions to prevent surgical site infections in the theoretical course taught by traditional method
Study: NCT06752733

Intervention type: PROCEDURE
Intervention: electrical cardioversion
Description: synchronized electrical shocks to restore normal sinus rhythm in patients with atrial fibrillation, performed under sedation
Study: NCT06756061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone + Jakavi(ruxolitinib)
Description: The experimental group will receive ruxolitinib 10 mg orally twice daily (BID) and prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease. (However, after the 48-week mark, participants in the ruxolitinib treatment group may continue to receive ruxolitinib for an additional maximum of 2 years, based on the investigator's judgment regarding the need for ongoing treatment. The total duration of ruxolitinib administration will not exceed 3 years.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: The control group will receive prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease.
Study: NCT06752447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNF2007
Description: LNF2007，9 dose groups:0.2μg/kg、1μg/kg、5μg/kg、20μg/kg、60μg/kg、120μg/kg、240μg/kg、360μg/kg、540μg/kg（0.2\~5μg/kg for accelerated titration, and i3+3 ramp-up starting from 20μg/kg dose group），IV, infusion time 60min±10min, Q4W, until disease progression 、intolerable toxicity or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.